Premium
Assessment of dendritic cell number and radiosensitivity in laryngeal tumours
Author(s) -
Nix P.,
Stafford N.,
Cawkwell L.,
Greenman J.
Publication year - 2005
Publication title -
clinical otolaryngology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.914
H-Index - 68
eISSN - 1749-4486
pISSN - 1749-4478
DOI - 10.1111/j.1365-2273.2004.00948.x
Subject(s) - medicine , radioresistance , radiation therapy , larynx , cancer , head and neck cancer , stage (stratigraphy) , biopsy , laryngeal neoplasm , oncology , surgery , radiology , paleontology , biology
Objectives: Radiotherapy is one of the principal treatment modalities for many types of head and neck tumour; what effects the dendritic cell (DC) population may have on treatment outcome have not been critically evaluated in laryngeal cancer. Design: Retrospective, case‐controlled study using immunohistochemistry to investigate the presence of S‐100 positive DC in pre‐treatment, archival biopsy tissue of early stage laryngeal cancers. Setting: Patients with laryngeal cancer treated with radiotherapy in Head and Neck Departments in England. Participants: Patients diagnosed with early stage laryngeal cancer, treated with single modality radiotherapy with curative intent. Radioresistant tumours ( n = 22), defined as recurrent tumours within 12 months of therapy. Radiosensitive tumours ( n = 22), defined as no recurrence with a minimum follow‐up of 36 months. Main outcome measures: Density of S‐100 staining DC on three ×200 magnified microscopic fields. Results: DC were present in approximately equal numbers in both radioresistant and radiosensitive laryngeal tumour pre‐treatment biopsies and therefore density did not correlate with radiotherapy treatment outcome ( P = 0.420). Conclusion: There is no intrinsic deficiency in DC number in radioresistant laryngeal tumours meaning that such tumours could potentially benefit from vaccination strategies that enhance the specific anti‐tumour immune response.